Mary M. Rozenman

2015

In 2015, Mary M. Rozenman earned a total compensation of $1.1M as Senior Vice President, Corporate Development and Strategy at Aimmune Therapeutics.

Compensation breakdown

Non-Equity Incentive Plan$90,700
Option Awards$719,157
Salary$252,083
Total$1,061,940

Rozenman received $719.2K in option awards, accounting for 68% of the total pay in 2015.

Rozenman also received $90.7K in non-equity incentive plan and $252.1K in salary.

Rankings

In 2015, Mary M. Rozenman's compensation ranked 7,651st out of 13,638 executives tracked by ExecPay. In other words, Rozenman earned more than 43.9% of executives.

ClassificationRankingPercentile
All
7,651
out of 13,638
44th
Division
Manufacturing
2,899
out of 5,190
44th
Major group
Chemicals And Allied Products
1,047
out of 1,854
44th
Industry group
Drugs
844
out of 1,528
45th
Industry
Pharmaceutical Preparations
664
out of 1,182
44th
Source: SEC filing on April 12, 2016.

Rozenman's colleagues

We found two more compensation records of executives who worked with Mary M. Rozenman at Aimmune Therapeutics in 2015.

2015

Stephen Dilly

Aimmune Therapeutics

Chief Executive Officer

2015

Warren DeSouza

Aimmune Therapeutics

Chief Financial Officer

In-depth

You may also like